Intravesical Thio-tepa in the Immediate Postoperative Period in Patients with Recurrent Transitional Cell Carcinoma of the Bladder

Publisher Website
Google Scholar
Abstract
Recurrent transitional cell carcinoma was treated with prophylactic intravesical thio-tepa [triethylenethiophosphoramide] in 22 cases. Group 1 patients were treated with 30 mg twice daily for the first 3 days postoperatively. Group 2 patients were given additional treatment at increasing intervals indefinitely. Before therapy control patients averaged 1 recurrence every 9.5 mo. Group 1 patients averaged 1 recurrence per 33 mo. Group 2 patients averaged 1 recurrence per 41 mo. Leukopenia occurred in 2 patients. Thio-tepa can be given safely in the immediate postoperative period and is effective in decreasing the recurrence rate of superficial bladder tumors.